Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 4/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | GRM5 | P41594 | 3/20 | 0.38 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.37 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.37 |
| ▸ | ITGAL | P20701 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 2/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10158539 | 0.81 | MAPT (0.42) | MAP3K14MAPTKDM4ENPC1ALDH1A1 | |
| SCHEMBL769070 | 0.78 | MAOB (0.42) | MAPTLMNAMAOBMAOAGRM5 | |
| SCHEMBL30401806 | 0.78 | ITGB1 (0.40) | MAPTMAOBMAOAGRM5ITGB2 | |
| SCHEMBL9923781 | 0.78 | MAOA (0.46) | MAPTLMNAMAOBMAOAGRM5 | |
| SCHEMBL13506273 | 0.78 | MAOB (0.39) | MAPTLMNAMAOBMAOAGRM5 | |
| SCHEMBL12431229 | 0.78 | ITGB1 (0.40) | MAPTMAOBMAOAGRM5ITGB2 | |
| SCHEMBL31411168 | 0.77 | MAPT (0.51) | MAPTLMNAMAOBKDM4EALDH1A1 | |
| SCHEMBL12316566 | 0.77 | MAPT (0.51) | MAPTLMNAMAOBKDM4EALDH1A1 | |
| SCHEMBL2156974 | 0.77 | ALDH1A1 (0.36) | MAPTLMNAMAOBMAOAGRM5 | |
| SCHEMBL11476070 | 0.76 | KDM4E (0.38) | MAPTLMNAMAOBMAOAGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233087-B1 | GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTORS | AXOVANT SCIENCES GMBH (DE) | 2019-10-02 | — | — | EP | disclosed |
| WO-2019070742-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK 1) INHIBITOR COMPOUNDS | SIDECAR THERAPEUTICS, INC. (US) | 2019-04-11 | — | — | WO | disclosed |
| US-20120071506-A1 | METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES | GALLEY GUIDO (DE) | 2012-03-22 | — | — | US | disclosed |
| US-7718809-B2 | Chromane substituted benzimidazole derivatives as acid pump antagonists | RAQUALIA PHARMA INC. (JP) | 2010-05-18 | — | — | US | disclosed |
| EP-1893197-B1 | CHROMANE SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS ACID PUMP ANTAGONISTS | RAQUALIA PHARMA INC (JP) | 2009-09-09 | — | — | EP | disclosed |
| EP-1981499-A1 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-20080214519-A1 | Chromane Substituted Benzimidazole Derivatives as Acid Pump Antagonists | RAQUALIA PHARMA INC. (JP) | 2008-09-04 | — | — | US | disclosed |
| EP-1893197-A1 | CHROMANE SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS ACID PUMP ANTAGONISTS | Pfizer, Inc. (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20070197620-A1 | Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007085558-A1 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| WO-2006134460-A1 | CHROMANE SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS ACID PUMP ANTAGONISTS | PFIZER JAPAN INC. (JP) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071506-A1 | METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES | CRY1, PER2, GPR119 | MAP3K14 2717/4885MAPT 31/4885LMNA 1909/4885 |
| US-20080214519-A1 | Chromane Substituted Benzimidazole Derivatives as Acid Pump Antagonists | HRH2, HRH4, HRH1 | MAP3K14 2415/4885MAPT 4797/4885LMNA 4444/4885 |
| US-20070197620-A1 | Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles | CRY1, PER2, GPR119 | MAP3K14 2855/4885MAPT 33/4885LMNA 1894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.